Objective In order to explore the changes and their clinical significance of peripheral blood tropomyosin-4(TPM4)and cofilin-1(CFL1)mRNA expression and antibody levels in patients with chronic spontaneous urticaria(CSU)before and after treatment.Methods Sixty patients with severe CSU(urticaria activity score over 7 days(UAS7)≥28)which from Pudong New Area People's Hospital of Shanghai from January to June 2023 were selected,and they were enrolled as the CSU group.After treatment with antihistamines(Mizolastine sustained-release tablets)at week 12,CSU patients were classified into effective(UAS7<7,n=41)and ineffective groups(UAS7≥7,n=19)based on their UAS7 score.Thirty healthy subjects undergoing physical examinations during the same period were selected as the control group.The mRNA expression of TPM4 and CFL1 was detected by quantitative real time polymerase chain reaction(RT-qPCR),and the antibody levels of peripheral blood TPM4 and CFL1 were determined by enzyme-linked immunosorbent assay(ELISA).Then the mRNA and antibody levels of TPM4 and CFL1 in the four groups were compared.Results The expression levels of TPM4 mRNA and antibody levels in the peripheral blood of severe CSU patients were higher than those in the control group,but the expression of CFL1 was lower than that in the control group.After 12 weeks of treatment with antihistamines,the expression levels of TPM4 mRNA and antibody in the effective group decreased significantly,while there were no significant differences in the expression of CFL1 mRNA and antibody in the peripheral blood before and after treatment.Conclusion TPM4 and CFL1 can serve as biological markers for monitoring severe CSU patients,and TPM4 can also be one of the indicators for evaluating the efficacy of antihistamine therapy.
NETL
NSTL
万方数据
